Skip to main content

Avenue Therapeutics, Inc. (ATXI)

NASDAQ: ATXI · IEX Real-Time Price · USD
1.54
+0.01 (0.65%)
After-hours:Sep 22, 2021 7:38 PM EDT
1.53
-0.02 (-1.29%)
At close: Sep 22, 4:00 PM
Market Cap25.34M
Revenue (ttm)n/a
Net Income (ttm)-3.97M
Shares Out16.56M
EPS (ttm)-0.24
PE Ration/a
Forward PE17.99
Dividendn/a
Ex-Dividend Daten/a
Volume45,004
Open1.54
Previous Close1.55
Day's Range1.51 - 1.56
52-Week Range1.50 - 11.58
Beta0.60
AnalystsBuy
Price Target12.00 (+684.3%)
Est. Earnings DateNov 3, 2021

About ATXI

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.

IndustryPharmaceuticals
IPO DateJun 27, 2017
Employees4
Stock ExchangeNASDAQ
Ticker SymbolATXI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ATXI stock is "Buy." The 12-month stock price forecast is 12.00, which is an increase of 684.31% from the latest price.

Price Target
$12.00
(684.31% upside)
Analyst Consensus: Buy

News

Why Novavax, Orphazyme, Avenue Therapeutics Shares Are Moving Monday

Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc. (NASDAQ: ATXI) are among the biggest movers among biopharma stocks Monday. Novavax Finally Releases Phase 3 COVID...

Other symbols:NVAXORPH
3 months ago - Benzinga

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced ...

3 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI

New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such investor...

5 months ago - Newsfile Corp

Avenue Therapeutics (ATXI) Sees Hammer Chart Pattern: Time to Buy?

Avenue Therapeutics (ATXI) has been struggling lately, but the selling pressure may be coming to an end soon

5 months ago - Zacks Investment Research

Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol

The FDA Has Not Provided a Decision Regarding the NDA The FDA Has Not Provided a Decision Regarding the NDA

5 months ago - GlobeNewsWire

Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that...

9 months ago - GlobeNewsWire

Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that...

9 months ago - GlobeNewsWire

Avenue Therapeutics' Pain Drug Gets Complete Response Letter

Avenue Therapeutics' (ATXI) NDA seeking an approval for its pipeline candidate tramadol to treat postoperative pain gets a CRL from the FDA, based on potential safety concerns. Shares down.

11 months ago - Zacks Investment Research

Avenue Therapeutics Sinks As FDA Rejects Opioid Pain Drug On Safety Concerns

Shares of micro-cap biopharma Avenue Therapeutics Inc (NASDAQ: ATXI) are plummeting on above-average volume after a binary event panned out against the company. What Happened: New York-based Avenue said...

11 months ago - Benzinga

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Management to Host Conference Call at 8:30 a.m. ET Management to Host Conference Call at 8:30 a.m. ET

11 months ago - GlobeNewsWire

Avenue Therapeutics Announces Publication of a Review of IV Tramadol

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announc...

1 year ago - GlobeNewsWire

Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2

Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.

1 year ago - Zacks Investment Research

Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported...

1 year ago - GlobeNewsWire

What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?

Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.

1 year ago - Zacks Investment Research

Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know

Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.30, moving -1.9% from the previous trading session.

1 year ago - Zacks Investment Research

Avenue Therapeutics, Inc. (ATXI) Stock Sinks As Market Gains: What You Should Know

Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.40, moving -1.61% from the previous trading session.

1 year ago - Zacks Investment Research

Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results

Publication highlights IV tramadol 50 mg demonstrated a statistically significant benefit (p-value < 0.05) over placebo for primary and all key secondary efficacy endpoints Publication highlights IV tra...

1 year ago - GlobeNewsWire

Is Avenue Therapeutics (ATXI) Stock Outpacing Its Medical Peers This Year?

Is (ATXI) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Avenue Therapeutics, Inc. (ATXI) Upgraded to Strong Buy: Here's What You Should Know

Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

Avenue Therapeutics' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Avenue Therapeutics

1 year ago - Zacks Investment Research

Is Avenue Therapeutics (ATXI) Outperforming Other Medical Stocks This Year?

Is (ATXI) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

5 Low-Beta Stocks to Beat Renewed Coronavirus Concerns

To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.

Other symbols:BJFROICLKPRQR
1 year ago - Zacks Investment Research

4 Affordable Breakout Stocks for Stunning Returns

Selecting breakout stocks continue to be one of the most popular methods utilized by active investors.

Other symbols:CALXECOMMGIC
1 year ago - Zacks Investment Research

Avenue Therapeutics Announces Publications in Peer-Reviewed Journals

NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...

1 year ago - GlobeNewsWire

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

Other symbols:CNCEMEIPNERVOCUL
1 year ago - Zacks Investment Research